Entrada Therapeutics announced that Nathan Dowden, current Chief Operating Officer of Entrada Therapeutics, has been promoted to President and Chief Operating Officer, effective as of January 1, 2024. Nate joined Entrada in 2019 and has 30 years of strategy, investment, and operational experience in the healthcare sector.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRDA:
- Entrada Therapeutics price target lowered to $20 from $25 at H.C. Wainwright
- Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
- Entrada completes dosing for first, second cohorts Phase 1 ENTR-601-44-101
- Entrada Therapeutics expects cash to fund requirements through 2025
- Entrada Therapeutics reports Q3 EPS $1.02, consensus (74c)